As­traZeneca touts a fresh cut of Farx­i­ga da­ta tar­get­ing di­a­betes pa­tients with chron­ic kid­ney dis­ease

As the SGLT2 race for di­a­betes turns hot, As­traZeneca — one of the ear­li­est play­ers in the field — has laid out da­ta demon­strat­ing its drug’s ben­e­fits for a sub­set of type 2 di­a­bet­ics.

Farx­i­ga (da­pagliflozin) was com­pared against a place­bo among type 2 di­a­betes pa­tients with a mod­er­ate stage of chron­ic kid­ney dis­ease in a Phase III study dubbed De­rive. The 321-pa­tient study met its pri­ma­ry end­point of chang­ing he­mo­glo­bin A1C (HbA1C) and all three of its sec­ondary end­points.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.